220 related articles for article (PubMed ID: 10462245)
1. Safety and immunogenicity of MF59-adjuvanted influenza vaccine in the elderly.
De Donato S; Granoff D; Minutello M; Lecchi G; Faccini M; Agnello M; Senatore F; Verweij P; Fritzell B; Podda A
Vaccine; 1999 Aug; 17(23-24):3094-101. PubMed ID: 10462245
[TBL] [Abstract][Full Text] [Related]
2. Safety and immunogenicity of an inactivated subunit influenza virus vaccine combined with MF59 adjuvant emulsion in elderly subjects, immunized for three consecutive influenza seasons.
Minutello M; Senatore F; Cecchinelli G; Bianchi M; Andreani T; Podda A; Crovari P
Vaccine; 1999 Jan; 17(2):99-104. PubMed ID: 9987141
[TBL] [Abstract][Full Text] [Related]
3. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine and an MF59-adjuvanted influenza vaccine after concomitant vaccination in ⩾60-year-old adults.
Song JY; Cheong HJ; Hyun HJ; Seo YB; Lee J; Wie SH; Choi MJ; Choi WS; Noh JY; Yun JW; Yun JG; Kim WJ
Vaccine; 2017 Jan; 35(2):313-320. PubMed ID: 27919632
[TBL] [Abstract][Full Text] [Related]
4. The adjuvanted influenza vaccines with novel adjuvants: experience with the MF59-adjuvanted vaccine.
Podda A
Vaccine; 2001 Mar; 19(17-19):2673-80. PubMed ID: 11257408
[TBL] [Abstract][Full Text] [Related]
5. Safety and immunogenicity of an MF59-adjuvanted A/H1N1 pandemic influenza vaccine in children from three to seventeen years of age.
Knuf M; Leroux-Roels G; Rümke HC; Abarca K; Rivera L; Lattanzi M; Pedotti P; Arora A; Kieninger-Baum D; Della Cioppa G
Vaccine; 2015 Jan; 33(1):174-81. PubMed ID: 25444803
[TBL] [Abstract][Full Text] [Related]
6. Enhanced immunogenicity of seasonal influenza vaccines in young children using MF59 adjuvant.
Vesikari T; Pellegrini M; Karvonen A; Groth N; Borkowski A; O'Hagan DT; Podda A
Pediatr Infect Dis J; 2009 Jul; 28(7):563-71. PubMed ID: 19561422
[TBL] [Abstract][Full Text] [Related]
7. Immunogenicity and safety of concomitant MF59-adjuvanted influenza vaccine and 23-valent pneumococcal polysaccharide vaccine administration in older adults.
Song JY; Cheong HJ; Tsai TF; Chang HA; Choi MJ; Jeon JH; Kang SH; Jeong EJ; Noh JY; Kim WJ
Vaccine; 2015 Aug; 33(36):4647-52. PubMed ID: 25980426
[TBL] [Abstract][Full Text] [Related]
8. Increased immunogenicity of the MF59-adjuvanted influenza vaccine compared to a conventional subunit vaccine in elderly subjects.
Gasparini R; Pozzi T; Montomoli E; Fragapane E; Senatore F; Minutello M; Podda A
Eur J Epidemiol; 2001; 17(2):135-40. PubMed ID: 11599686
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the reactogenicity and immunogenicity of a split and a subunit-adjuvanted influenza vaccine in elderly subjects.
Squarcione S; Sgricia S; Biasio LR; Perinetti E
Vaccine; 2003 Mar; 21(11-12):1268-74. PubMed ID: 12559808
[TBL] [Abstract][Full Text] [Related]
10. MF59-adjuvanted influenza vaccine confers superior immunogenicity in adult subjects (18-60 years of age) with chronic diseases who are at risk of post-influenza complications.
Baldo V; Baldovin T; Floreani A; Carraro AM; Trivello R;
Vaccine; 2007 May; 25(20):3955-61. PubMed ID: 17383057
[TBL] [Abstract][Full Text] [Related]
11. [Study on the safety and immunogenicity of MF59-adjuvanted influenza subunit vaccine in Chinese elderly].
Li RC; Fang HH; Li YP; Liu YP; Nong Y; Huang GB
Zhonghua Liu Xing Bing Xue Za Zhi; 2008 Jun; 29(6):548-51. PubMed ID: 19040034
[TBL] [Abstract][Full Text] [Related]
12. Assessment of the immunogenicity and safety of varying doses of an MF59®-adjuvanted cell culture-derived A/H1N1 pandemic influenza vaccine in Japanese paediatric, adult and elderly subjects.
Fukase H; Furuie H; Yasuda Y; Komatsu R; Matsushita K; Minami T; Suehiro Y; Yotsuyanagi H; Kusadokoro H; Sawata H; Nakura N; Lattanzi M
Vaccine; 2012 Jul; 30(33):5030-7. PubMed ID: 22472791
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the immunogenicity and safety of the conventional subunit, MF59-adjuvanted, and intradermal influenza vaccines in the elderly.
Seo YB; Choi WS; Lee J; Song JY; Cheong HJ; Kim WJ
Clin Vaccine Immunol; 2014 Jul; 21(7):989-96. PubMed ID: 24828092
[TBL] [Abstract][Full Text] [Related]
14. Immunogenicity and safety of cell-derived MF59®-adjuvanted A/H1N1 influenza vaccine for children.
Knuf M; Leroux-Roels G; Rümke H; Rivera L; Pedotti P; Arora AK; Lattanzi M; Kieninger D; Cioppa GD
Hum Vaccin Immunother; 2015; 11(2):358-76. PubMed ID: 25621884
[TBL] [Abstract][Full Text] [Related]
15. Antibody induction by virosomal, MF59-adjuvanted, or conventional influenza vaccines in the elderly.
de Bruijn I; Meyer I; Gerez L; Nauta J; Giezeman K; Palache B
Vaccine; 2007 Dec; 26(1):119-27. PubMed ID: 18063446
[TBL] [Abstract][Full Text] [Related]
16. A dose-ranging study of MF59(®)-adjuvanted and non-adjuvanted A/H1N1 pandemic influenza vaccine in young to middle-aged and older adult populations to assess safety, immunogenicity, and antibody persistence one year after vaccination.
Reisinger KS; Holmes SJ; Pedotti P; Arora AK; Lattanzi M
Hum Vaccin Immunother; 2014; 10(8):2395-407. PubMed ID: 25424947
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the safety, tolerability, and immunogenicity of a MF59-adjuvanted influenza vaccine and a non-adjuvanted influenza vaccine in non-elderly adults.
Frey S; Poland G; Percell S; Podda A
Vaccine; 2003 Oct; 21(27-30):4234-7. PubMed ID: 14505903
[TBL] [Abstract][Full Text] [Related]
18. MF59™ as a vaccine adjuvant: a review of safety and immunogenicity.
El Sahly H
Expert Rev Vaccines; 2010 Oct; 9(10):1135-41. PubMed ID: 20923265
[TBL] [Abstract][Full Text] [Related]
19. MF59-adjuvanted influenza vaccine (FLUAD) in children: safety and immunogenicity following a second year seasonal vaccination.
Vesikari T; Groth N; Karvonen A; Borkowski A; Pellegrini M
Vaccine; 2009 Oct; 27(45):6291-5. PubMed ID: 19840662
[TBL] [Abstract][Full Text] [Related]
20. Long-term and cross-reactive immunogenicity of inactivated trivalent influenza vaccine in the elderly: MF59-adjuvanted vaccine versus unadjuvanted vaccine.
Song JY; Cheong HJ; Noh JY; Seo YB; Choi WS; Cho GJ; Hwang TG; Kim WJ
J Med Virol; 2013 Sep; 85(9):1591-7. PubMed ID: 23852684
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]